{
  "ticker": "CHM",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971958",
  "id": "02971958",
  "pages": 47,
  "price_sensitive": false,
  "date": "20250723",
  "time": "1633",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m284q6836ds8.pdf",
  "summary": "**Capital Raising Announcement Summary**  \n\n- **Structure**:  \n  - **Placement**: Issuance of 141,250,000 new shares (Lind Shares) at AUD 0.004/share.  \n  - **Attaching Options**: 141,250,000 options (1:1 with Lind Shares), exercisable at AUD 0.004 within 8 months of grant.  \n  - **Contingent Options**: Up to 141,250,000 options (1:1 for exercised Attaching Options within 5 months), exercisable at AUD 0.005.  \n\n- **Total Capital Raised**:  \n  - **No new funds** raised from Lind Shares (issued to settle prior obligations under the terminated Lind Subscription Agreement).  \n  - **Potential additional AUD 1,271,250** if all Contingent Options are exercised.  \n\n- **Key Dates**:  \n  - **Grant Date (for Attaching Options)**: 28 July 2025.  \n  - **Contingent Option Eligibility Cut-off**: 28 December 2025.  \n\n- **Operational Impact**:  \n  - Proceeds from exercised options (if any) to fund clinical pipeline and working capital.  \n  - **Post-issue capital structure**: Fully diluted shares on issue increase to ~8.34 billion (including options/performance rights).  \n\n- **Material Risks**:  \n  - High dilution risk due to large option issuances.  \n  - Clinical trial, regulatory, and commercialization risks for cell therapy pipeline.  \n\n**Rationale**: Settlement of legacy obligations via equity, with contingent funding upside tied to option exercises. Minimal immediate liquidity impact.",
  "usage": {
    "prompt_tokens": 26300,
    "completion_tokens": 341,
    "total_tokens": 26641,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-23T06:54:42.219679"
}